在下肢再血管化后,里瓦罗克萨班加上阿司匹林
Graham R McClure1,2, John Eikelboom1,3
1Population Health Research Institute, Hamilton, ON, Canada.
低剂量里瓦洛克萨班加上阿司匹林在下肢再血管化后显著降低了不良心脏和四肢事件. 这种组合疗法提供了一个优越的抗血栓策略,与单独的阿司匹林相比,尽管指导方针的采用有限.
科学领域:
- 心血管医学 心血管医学
- 血管外科 血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 周围再血管患者面临高率的不良心脏和四肢事件.
- 目前的抗血小板治疗不足以降低风险.
- 优化抗血栓策略至关重要.
研究的目的:
- 为了审查Rivaroxaban的个人资料.
- 总结里瓦洛克萨班加阿司匹林在重血管化后的疗效和安全性.
- 检查采用这种组合疗法的障碍.
主要方法:
- 对最近的大型随机试验的审查.
- 对药物概况和临床数据的分析.
- 检查社会指导方针的建议.
主要成果:
- 里瓦罗克萨班加上阿司匹林可以减少心脏和四肢事件.
- 这种组合保持了可接受的出血概况.
- 目前的指导方针没有纳入这些证据.
结论:
- 里瓦罗克萨班加阿司匹林是唯一一种已被证明可以减少心脏和四肢事件的治疗方案.
- 迫切需要更新社会准则.
- 对双重抗血小板治疗的进一步研究是有必要的.
更多相关视频
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
